As one of the first worldwide suppliers of the influenza vaccines, and now, with over 70 years of innovation in influenza ...

The National Medical Products Administration approved Dupixent as an add-on maintenance treatment for adults with ...

AbbVie Humira, Pfizer/BioNTech COVID-19 shot may not make top 10 pharma drugs in 2024, with Novo Nordisk Ozempic and ...

Bristol Myers gains FDA approval for a new schizophrenia drug. HHS declares a health emergency in Georgia due to Hurricane ...

The Ministry of  Health (MoH) and the Ghana Health Service (GHS) have launched the AYA-Integrated Healthcare Initiative (IHI) to tackle ...

Dupixent may help some people with inadequately controlled COPD who have a type of lung inflammation that worsens symptoms.

The U.S. FDA has approved Cobenfy, a dual M1/M4 muscarinic agonist that offers a fundamentally different approach to treating schizophrenia. The fixed dose combination of xanomeline-trospium is the ...

Health-care companies ticked up, but lost ground during a generally positive week for the stock market amid fears about the implications of a tight presidential race for health-care regulation.

Shares of Regeneron Pharmaceuticals and Sanofi edged higher Friday after their drug to treat chronic obstructive pulmonary ...

Companies have been involved in at least $250 billion of spinoffs and asset sales this year, data compiled by Bloomberg show.

Following the FDA's green light for a combo regimen of Sanofi’s Sarclisa in patients with newly diagnosed multiple myeloma ...

The agency converted a prior accelerated approval to a traditional approval based on results from the LIBRETTO-531 trial.